- Open
- 6.35
- High
- 6.60
- Low
- 6.20
- Close
- 6.20
- Change
- -0.20 (-3.13%)
- Volume
- 642,496
| 6 Oct 2026 | 07:00:03 | POLB001 CRS Patent Granted in South Korea |
| 29 Sept 2026 | 07:00:04 | Interim Results for the six months to 30 June 2026 |
| 28 Sept 2026 | 07:00:12 | POLB 001 TOPICAL trial recruitment update |
| 24 Sept 2026 | 07:00:08 | Interim data from POLB 001 TOPICAL clinical trial |
| 14 Sept 2026 | 11:58:40 | Notification of Major Holdings |
| 30 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 22 Jun 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 20 May 2023 | Annual Report and Accounts (to 2022-12-31) |
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company focused on developing medicines to address unmet medical needs, particularly in the area of infectious diseases. Its clinical programs target large addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS). The company aims to progress its pipeline programs cost-effectively to position them for potential partnering and commercialization. Poolbeg operates primarily in the research and development phase, with ongoing projects such as POLB 001, which is being developed for CRS.
| 6 Oct 2026 | 07:00:03 | POLB001 CRS Patent Granted in South Korea |
| 29 Sept 2026 | 07:00:04 | Interim Results for the six months to 30 June 2026 |
| 28 Sept 2026 | 07:00:12 | POLB 001 TOPICAL trial recruitment update |
| 24 Sept 2026 | 07:00:08 | Interim data from POLB 001 TOPICAL clinical trial |
| 14 Sept 2026 | 11:58:40 | Notification of Major Holdings |
| 30 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 22 Jun 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 20 May 2023 | Annual Report and Accounts (to 2022-12-31) |
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company focused on developing medicines to address unmet medical needs, particularly in the area of infectious diseases. Its clinical programs target large addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS). The company aims to progress its pipeline programs cost-effectively to position them for potential partnering and commercialization. Poolbeg operates primarily in the research and development phase, with ongoing projects such as POLB 001, which is being developed for CRS.
